The Roadmap for Making Clinical Trials More Diverse and Representative
Diversity in clinical trials is a change that needs to be made in order to make all efforts more efficient and develop a better ending result for patients. Karla Feghali and Laura Fernandes detail why this is so necessary moving forwards.
Real-World Data is Essential for Illuminating and Addressing Disparities in Care
RWD can help us address one of the most challenging systemic issues in healthcare: disparities in health outcomes perpetuated by uneven access to services and the unconscious bias of humans and technology
Rewriting the Oncology Patient’s Journey with Real-World Data
Life science stakeholders are committed to making the path to positive outcomes less frightening and convoluted for patients. With breakthrough treatments and innovative therapies targeted to the toughest of cancers, the industry has made significant progress with guiding patients toward longer, healthier lives.
Roche is Validating the Utility of Real-World Evidence as a comparator to Single-arm Clinical Trials
A new study from Roche finds concerns around real-world evidence as a comparator to single-arm trials may be unfounded.
The Questions You Should Be Asking When Evaluating Real-World Data
With a thriving data marketplace and rising enthusiasm, it’s easy to get excited by promises and possibilities of what real-world data (RWD) has to offer, but not all RWD is created equal and it’s important to remember that quality is more important than quantity
Data Standardizations Support Collaboration Across RWD Stakeholders
Most real-world data (RWD) sets aren’t usable directly from the source. Adopting established standards to curate reliable, sharable insights is key for unleashing the potential of rich data assets. Read how COTA is working with HemOnc.org, OMOP, and Health Language to create the deepest, longitudinal, highest quality RWD to drive cancer research.
COTA, Inc. and Kite Collaborate To Expand the Use of Real-World Data To Drive Faster, Effective Treatments for Cancers
COTA’s Real-World Data Will Complement Single-Arm Clinical Trials to Accelerate Cancer Research Benefiting Patients
2021: The Year of Real-World Data
The pandemic has specifically accelerated the pace of innovation in the realm of real-world data, fueling a number of trends that we expect will carry on and pick up steam post-COVID.
COTA’s Podcast Brings Together RWD Experts from Across the Industry
Real World Talk with COTA brings together thought leaders across the industry to discuss RWD and its impact on drug development and cancer care. Meet some of our recent guests…
COTA Presents Posters at ASH Annual Meeting, Reviewing Complexities of Generating RWD and How it Complements Traditional Clinical Trial Data
Research Presented Alongside MMRF and HUMC Evaluates Opportunity for RWE to Study Patient Treatment & Outcomes in Routine Cancer Care
